Maryland is currently home to 2858 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRĪ±) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Recruiting
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Maryland Oncology Hematology, Rockville, Maryland
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Study of Descartes-30 in Acute Respiratory Distress Syndrome
Recruiting
Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2023
Locations: University of Maryland Medical Center Medical Center, Baltimore, Maryland
Conditions: Acute Respiratory Distress Syndrome, Covid19
Study of Infigratinib in Children With Achondroplasia
Recruiting
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK S... Read More
Gender:
All
Ages:
Between 3 years and 11 years
Trial Updated:
02/06/2023
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Achondroplasia
The PROMISE Study: Duavee in Women With DCIS
Recruiting
The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (DuaveeĀ®) causes any changes in the proliferation markers within the breast tissue of the study subjects. The study drug is approved by the US Food and Drug Administration in healthy postmenopausal women to treat certain symptoms of menopause such as hot flashes. Since it is not approved in women with DCIS, its use in this study is experimental. This study will also look at whether taking t... Read More
Gender:
Female
Ages:
Between 18 years and 79 years
Trial Updated:
02/06/2023
Locations: John's Hopkins University, Baltimore, Maryland
Conditions: Ductal Breast Carcinoma In Situ, Postmenopausal
Stress Hydrocortisone In Pediatric Septic Shock
Recruiting
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL), as assessed at 28 days follo... Read More
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
02/02/2023
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Septic Shock
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Medstar Franklin Square, Baltimore, Maryland
Conditions: Colorectal Cancer
Nebulised Heparin in Patients With Severe COVID-19
Recruiting
The Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19 Requiring mechanical ventilation Meta-Trial (CHARTER-MT) is a prospective collaborative individual patient data analysis of randomised controlled trials and early phase studies. Individual studies are being conducted in multiple countries, including Australia, Ireland, the USA, and the UK. Mechanically ventilated patients with confirmed or strongly suspected SARS-CoV-2 infection, hypoxaemia and an acute... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Frederick Health Hospital, Frederick, Maryland
Conditions: Covid19, Respiratory Failure
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
Recruiting
Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
Gender:
Male
Ages:
Between 22 years and 65 years
Trial Updated:
01/26/2023
Locations: Chesapeake, Hanover, Maryland
Conditions: Urethral Stricture
Ankle Robotics After Stroke
Recruiting
The randomized study (in Phase II of the U44) compares the efficacy and durability of 9 weeks (18 sessions) of robot-assisted physical therapy (PTR) versus physical therapy (PT) alone on foot drop as assessed by gait biomechanics (ankle angle at initial contact, peak swing ankle angle, number of heel-first strikes - % total steps, gait velocity) and blinded clinician assessment (dorsiflexion active range of motion, ankle muscle strength, assistive device needs).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2023
Locations: University of Maryland Rehabilitation & Orthopaedic Institute, Baltimore, Maryland
Conditions: Foot Drop, Stroke, Hemiparesis
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Baltimore, Maryland
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Biologic Mechanisms of Early Exercise After Intracerebral Hemorrhage
Recruiting
This study aims to determine whether in-bed cycle ergometry, early in the hospital course after a brain hemorrhage could balance damaging and reparative inflammation in the brain. Inflammatory factors of two groups of patients with brain hemorrhage will be compared, one group will receive in-bed cycling beginning 3 days after hemorrhage plus usual care and the other group will receive usual care only.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/23/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Intra Cerebral Hemorrhage, Stroke Hemorrhagic
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
Recruiting
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2023
Locations: American Oncology Partners of Maryland, PA, Bethesda, Maryland
Conditions: Chemotherapy-induced Nausea and Vomiting